Member Info for B2HS2L

Lab21 have collaborated before in developing Aspergillus fungus assays.

https://www.infectioncontroltoday.com/view/bd-and-lab21-collaborate-develop-aspergillus-assay

BD and Lab21 Collaborate to Develop Aspergillus Assay
August 3, 2011

BD Diagnostics, a segment of global medical technology company BD (Becton, Dickinson and Company), and Lab21, a leader in personalized healthcare, announce a collaboration to develop a state-of-the-art molecular diagnostic assay to detect the life-threatening Aspergillus fungus using the new fully automated BD MAX Molecular Testing System.

"The potential to detect Aspergillus in blood using real-time polymerase chain reaction is a topic of great interest to clinicians since it offers faster, more sensitive and more accurate diagnostic and screening strategies for the early and definitive detection of aspergillosis," says Graham Mullis, CEO of Lab21.

Infection caused by Aspergillus is a leading cause of infectious death in immunocompromised patients, with an estimated 10 million people at risk globally each year. Studies have shown that diagnosis of Aspergillus infection followed by antifungal treatment within the first 10 days of infection reduces mortality from 90 percent to 40 percent highlighting the need for rapid, accurate testing. Real-time polymerase chain reaction may offer significant advantages in sensitivity and specificity over the current culture techniques.

++++

Nice to know we have a head start.

Saintsmith -

I'm sure many companies have made an approach, the shear number of market disrupting technology breakthroughs should have ensured this interest.
However, GM wants to build a larger version of NCYT, and to assist him in this task the British and French governments have issued these:

New protections for UK businesses key to national security and fight against coronavirus :
https://www.gov.uk/government/news/new-protections-for-uk-businesses-key-to-national-security-and-fight-against-coronavirus

French Government protecting key Covid-19 players :
https://www.skadden.com/insights/publications/2020/05/france-moves-to-protect-strategic-assets

I'm sure there are circumstances where the existence of this legislation is a hinderance to a deal he feels deserves further consideration, but meanwhile his bigger / better NCYT continues to bloom.

Apart from the phase 1&2 update, we didn't hear anything about 'transplants'.
Guess we need a more appropriate strategy statement.

Airline is right about too much being released at once.
We needed bits of this sooner, to spread the load.

Otherwise a great update.

How many think we might have to revisit these levels again tomorrow?
Recommend this if you do.

I think we will, so add 1 to the score

From a Porky Post last night:

"Finally, with the market cap this low to fundamentals we are at serious risk of a takeover especially with the ongoing requirement for whole genome sequencing to pick up new variants and surge testing ."

Not sure how many are aware of these:

New protections for UK businesses key to national security and fight against coronavirus :
https://www.gov.uk/government/news/new-protections-for-uk-businesses-key-to-national-security-and-fight-against-coronavirus

French Government protecting key Covid-19 players :
https://www.skadden.com/insights/publications/2020/05/france-moves-to-protect-strategic-assets

Do these change your outlook?

Hi RBMInvest
Thanks for a great post that should have set us up for the day, if it were'nt for the sp drop :(
That said, I have some good news concerning a genomics partnership Primerdesign has had since September 2018.
It's very specific with an American company, but we could not ask for better genomics contacts on the other side of the pond:

RNS 13.09.2018 - https://www.lse.co.uk/rns/NCYT/novacyt-partners-with-applied-microarrays-qbb4zadobpqrevf.html
Novacyt Partners with Applied Microarrays

Paris, France and Camberley, UK - 13 September 2018 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its molecular testing division, Primerdesign Ltd. (Primerdesign), has partnered with Applied Microarrays, Inc. (AMI), a company that specialises in providing customised microarrays and manufacturing point-of-care (POC) and high throughput DNA and protein arrays, to offer comprehensive single nucleotide polymorphism (SNP) assay development.

Primerdesign will play an integral part in designing probes for AMI and their customers. The microarray based molecular diagnostic tests developed under this partnership will play a crucial role in the early diagnosis, as well as improve patient management and outcome. Primerdesign has thirteen years' experience in molecular assay design and this partnership highlights the division's pivotal role in assay development as it grows its relationships with leading diagnostic companies.

Working together, Primerdesign and AMI can provide a full suite of assay development services from probe designs, through to assay optimisation, regulatory and ultimately high volume manufacturing of SNP microarrays for use in POC as well as laboratory-based settings...

...Graham Mullis, Group CEO of Novacyt, added:

"I am delighted that we are entering into a partnership with AMI.
This partnership significantly expands our offering and geographic reach as we continue to expand our molecular products business.
++++

!!!! YEEEEHAAAAA !!!!

Dartron, -

No, - she is Executive Director and Chair of the COVID-19 Genomics UK (COG-UK) consortium.

....Germany and USA (to name two) are starting to add a lot more sequences to the database now.

It will be no surprise WHEN they uncover new virus mutations in their midst.

Do we do what Trump advised and stop testing?

No send for Ghost Busters, send for GM.

Well I'll be coming with you Dartron, - I'm not selling.
I suppose I could email 'BossaNova' and ask 'what does it take before you start taking measures to protect the sp'.
But I think we know there would be a deafening silence.

Yes, - you'll get to £12, but not sure when.
You probably read I was spiked for 5 months, April - September 2020.

With only 72 million shares available, and the fundamentals improving almost by the week, the bounce when it comes really will be worth waiting for.

Dartron -
I posted this last week:
https://www.dw.com/en/coronavirus-crisis-war-against-the-variants/av-56593444

04:30

Prof Sharon Peac*ck (Chief UK Virus Mutation Monitor)
"12 months ago UK was creating 50,000 genome sequences per year.
Present rate of UK genome sequencing is 27,000 per day".

Germany and USA (to name two) are starting to add a lot more sequences to the database now.

Genome sequencing is becoming much much faster for those with the latest equipment,
and thus much cheaper to produce.
I'm not concerned about profit margins, they will look after themselves.

Yes indeed Soder -
Just love this:
"152. The UK is a global leader in genome sequencing, which in positive cases allows the
identification of Variants of Concern, and continues to scale up its capacity. The
Government is also working with diagnostics providers to adapt PCR tests to detect
specific Variants of Concern once they have been identified. This, combined with
whole genome sequencing, should enable mutations to be detected more rapidly,
enabling action to be taken. The UK will also provide sequencing support for other
countries should they need it, helping to track variants wherever they appear in the
world and in turn shaping the UK’s border policies. Despite this progress, the risks
posed by Variants of Concern remain significant."

UK providing sequencing support.
...adapt PCR tests to detect specific Variants of Concern once they have been identified.

This sounds like a job for life for the only diagnostics provider adapting PCR tests to detect variants of concern.
Standby for more genome sequencing vacancies..

SC -
Up until last week we just emailed Mandy, and we got along like that.
Now we appear to be using FTI, and our questions disappear into a black hole.
Well that's progress.

Question, has anybody had a response from FTI at all?

GM doesn't want to answer questions, so this is suits him fine.

Suggest you read the annual reports, they are always a good start SC.

I have no idea how PR teams charge for their services.
However, does the term 'service level agreement' apply to any relationship twixt company and the PR company employed?

Ala

scenario a
Company hands PR advisor a stack of old RNS's and says 'don't embellish these'.
2 day turnaround - Reasonably cheap service.

scenario b
Company says I want each and every investor question answered.
1 day turnaround - Very expensive

scenario c
GM - Provides list of stock questions / answers. Says 'You are not empowered to answer anything else'.
5 day turnaround - Reasonably cheap service.

jm2c

SC -
At the bottom of all RNS you will find:

FTI Consulting (International)

Victoria Foster Mitchell / Mary Whittow

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com / mary.whittow@fticonsulting.com



FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 47

arnaud.decheffontaines@fticonsulting.com

++++

This isn't a recent addition.

The above was copied from a July 2020 RNS.

From the last RNS 02.02.2021:

"Novacyt's bioinformatics surveillance group has worked with a global network of virologists tracking variants to identify the mutations, or Single Nucleotide Polymorphisms (SNPs), critical to each variant.
From this analysis, Novacyt has developed and patented the SNPsig® portfolio, which is one of the first commercially available for variant detection.
The first three SNPsig® assays, launched today, enable the identification of the non-variant virus and the UK, South Africa or Brazil variants, as well as any variant carrying the N501Y mutation."

Specifically these RUO assays are:

SNPsig SARS-CoV-2 (N501Y) Detection Profile - Variants with N501Y mutation (UK, SA & Brazil)
SNPsig SARS-CoV-2 (201/501Y.V1) Detection Profile - UK
SNPsig SARS-CoV-2 (20H/501Y.V2) Detection Profile - SA

Today via twitter we were advised that another RUO assay had been released:
SNPsig SARS-CoV-2 (20J/501Y.V3) Detection Profile Brazil variant -
https://genesig.com/assets/files/SNPsig_SARS_CoV_2_20J_501YV3_HANDBOOK_version_100_HT.pdf

So now they can detect all 3 mutations at once, or one variant at a time.

For virus sequences gathered inside or outside the UK, it will be added to (and available to all via) the worldwide GISAID (Global Initiative on Sharing Avian Influenza Data) database.

Many nations have not been contributing virus sequences to the database, but now recognise the value of virus sequence contribution.
This is because they continually need reassurance the vaccines they provide to their citizens are still effective against all mutations.

Also from the last RNS:

"The tracking of variants could also contribute to the effectiveness of vaccination efforts, especially if, as described in recent publications, the emergence of variants may have an impact on vaccine efficaciousness. The SNPsig® assays offer the ability to track variants on-site and to generate a result in hours, compared to the current approach of next generation sequencing, which is typically constrained by limited capacity, cost and an off-site multi-day turnaround." ref https://jamanetwork.com/journals/jama/fullarticle/2776039

Only a government that does not have the health of the people at heart will not be willing to test which variants are circulating in the population, (and which new threats are emerging).
It won't be long before we hear what assistance WHO are willing to provide to poorer nations, who will be needing portable testing equipment for fast answers,
see https://www.youtube.com/watch?v=M9F1ZWxlehc

I'm waiting for the WHO to recognise the new SNP assay's ASAP.

@3.30 today

Kaeren,

Ref this link - bit.ly/2NQcWuS

It now contains four handbooks, the new product being:

SNPsig® SARS-CoV-2 (20J/501Y.V3) - Brazil variant version 3 :)

FTI consulting will also have a long list of subjects from GM they are not to discuss, starting with DHSC contracts.

B2HS2L

Posted in: NCYT

Posts: 2,242

Price: 747.00

No Opinion

Trying to let17 Feb 2021 17:05
you guys down gently.

I had a question for Mandy this morning.

No response until 16:45 when I got:

"Thank you for your interest in Novacyt S.A.

Your email has been forwarded to our communications team at Novacyt.group@fticonsulting.com.

Due to the large amount of interest in the company at this time, we cannot respond to all individual shareholder queries. Please see our website on www.novacyt.com for further information about the company. Any price sensitive information will be released via RNS in the usual way.

Kind regards,

Investor Relations"

:(
++++

FTI consulting listed at the bottom of each RNS.

https://inews.co.uk/news/uk/lockdown-announcement-roadmap-when-date-time-boris-johnson-covid-rules-update-watch-live-876013

When will Boris Johnson announce his roadmap to recovery?
The Prime Minister announced earlier this month that he would reveal the plan for the next stages of lockdown on Monday, Feb 22.

He will address MPs shortly after 3pm and, four hours later, the nation in a press conference from Downing Street, it has been reported.

This is the only timings for tomorrow's BJ 'Roadmap' speeches I could find tonight.